Presentation (CTI)

OBJECTIVES: This retrospective cohort study evaluates the healthcare cost and effectiveness of semaglutide in glycemic control, weight loss, and lipid profile improvement among patients with type 2 diabetes (T2D) in Israel
METHODS: The study utilized the electronic health records (EHR) of Leumit Health Services (LHS), identifying a cohort of 8,811 T2D patients who purchased semaglutide for at least 5 months between 2020 and 2023, and had BMI, serum glucose and HbA1c measurements in the 180 days prior to semaglutide treatment initiation. 6,359 of these patients were compared to a matched cohort of non-GLP-1 users in a 1:1 ratio, matched based on demographic, clinical, and comorbidity profiles using propensity score matching. The primary outcome was comparisons of healthcare costs and hospitalization days
RESULTS: The study showed a statistically significant reduction of 2.25 in hospitalization days and cost savings of 3,368 NIS per patient year for those treated with semaglutide
CONCLUSIONS: This study showed that using semaglutide for patients with T2D leads to cost savings in a relatively short period of time, the cost saving is mainly due to the improved clinical outcomes.